# US 10,501,546 B2 · Insulin immunoglobulin fusion proteins > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,501,546 B2 - Document ID: US10501546B2 - Status: Granted - Kind: B2 - Application number: 15/756,296 - Filed: 2016-09-02 - Published: 2019-01-24 - Granted: 2019-12-10 - Earliest claimed: 2015-09-04 - Assignees: The California Institute for Biomedical Research - Applicants: The California Institute for Biomedical Research - Inventors: Feng Wang; Matthew S. Tremblay; Travis Young; Nicole Alvarez; Yan Liu; Juanjuan Du; Peter G. Schultz - Web page: https://patentgrep.com/patent/US10501546B2 ## CPC - C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72} - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - C07K 14/62: Insulins - C07K 16/2854: {against selectins, e.g. CD62} - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2319/00: Fusion polypeptide - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Disclosed herein are immunoglobulin fusion proteins comprising an insulin therapeutic peptide and an immunoglobulin region that targets the insulin therapeutic peptide to the liver of an individual in need thereof. Further disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject, for example, diabetes and diabetes related conditions. ## Claims ### Claim 1 An immunoglobulin for specific binding to asialoglycoprotein receptor (ASGPR), the immunoglobulin comprising: a) a heavy chain sequence comprising (i) SEQ ID NO: 45, SEQ ID NO: 55, and SEQ ID NO: 47; or (ii) SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NO: 47; and b) a light chain sequence comprising SEQ ID NO: 48, SEQ ID NO: 49, and SEQ ID NO: 50. ### Claim 2 (depends on 1) The immunoglobulin of claim 1, comprising a CH1 domain. ### Claim 3 (depends on 1) The immunoglobulin of claim 1, wherein the immunoglobulin is humanized. ### Claim 4 (depends on 1) The immunoglobulin of claim 1, wherein the heavy chain sequence comprises SEQ ID NOS: 45, 55, and 47. ### Claim 5 (depends on 4) The immunoglobulin of claim 4, wherein the heavy chain sequence comprises a sequence at least about 95% identical to the framework of amino acid sequence of SEQ ID NO: 43. ### Claim 6 (depends on 4) The immunoglobulin of claim 4, wherein the heavy chain sequence comprises a sequence that differs from SEQ ID NO: 43 by no more than 2 amino acids. ### Claim 7 (depends on 4) The immunoglobulin of claim 4, wherein the heavy chain sequence comprises SEQ ID NO: 43. ### Claim 8 (depends on 7) The immunoglobulin of claim 7, wherein the heavy chain sequence comprises SEQ ID NO: 36. ### Claim 9 (depends on 8) The immunoglobulin of claim 8, wherein the heavy chain sequence comprises SEQ ID NO: 34. ### Claim 10 (depends on 1) The immunoglobulin of claim 1, wherein the heavy chain sequence comprises SEQ ID NOS: 45-47. ### Claim 11 (depends on 10) The immunoglobulin of claim 10, wherein the heavy chain sequence comprises a sequence at least about 95% identical to the framework of amino acid sequence of SEQ ID NO: 39. ### Claim 12 (depends on 10) The immunoglobulin of claim 10, wherein the heavy chain sequence comprises a sequence that differs from SEQ ID NO: 39 by no more than 2 amino acids. ### Claim 13 (depends on 10) The immunoglobulin of claim 10, wherein the heavy chain sequence comprises SEQ ID NO: 39. ### Claim 14 (depends on 13) The immunoglobulin of claim 13, wherein the heavy chain sequence comprises SEQ ID NO: 167. ### Claim 15 (depends on 1) The immunoglobulin of claim 1, wherein the light chain sequence comprises a sequence at least about 95% identical to the framework of amino acid sequence of SEQ ID NO: 41. ### Claim 16 (depends on 1) The immunoglobulin of claim 1, wherein the light chain sequence comprises a sequence that differs from SEQ ID NO: 41 by no more than 2 amino acids. ### Claim 17 (depends on 1) The immunoglobulin of claim 1, wherein the light chain sequence comprises SEQ ID NO: 41. ### Claim 18 (depends on 1) The immunoglobulin of claim 1, wherein the light chain sequence comprises a sequence at least about 95% identical to the framework of amino acid sequence of SEQ ID NO: 44. ### Claim 19 (depends on 1) The immunoglobulin of claim 1, wherein the light chain sequence comprises a sequence that differs from SEQ ID NO: 44 by no more than 2 amino acids. ### Claim 20 (depends on 1) The immunoglobulin of claim 1, wherein the light chain sequence comprises SEQ ID NO: 44.